-

bluebird bio to Host Second Quarter 2023 Financial Results Conference Call and Provide Commercial Update

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced it will hold a conference call to discuss second quarter 2023 financial results and provide a commercial update on Tuesday, August 8 at 8:00 a.m. ET. In addition to providing an overview of the business, the conference call will highlight the Company’s ongoing commercial launches of SKYSONA® and ZYNTEGLO® and the market opportunity for lovo-cel.

To access the call via telephone, please register at this link https://register.vevent.com/register/BI4fa1d86317c74333813f6827624e43ae to receive a dial in number and unique PIN to access the live conference call.

The live webcast of the call may be accessed by visiting the “Events & Presentations” page within the Investors & Media section of the bluebird website at http://investor.bluebirdbio.com. A replay of the webcast will be available on the bluebird website for 90 days following the event.

About bluebird bio, Inc.

bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.

With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.

Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds.

For more information, visit bluebirdbio.com or follow us on social media at @bluebirdbio, LinkedIn, Instagram and YouTube.

bluebird bio, ZYNTEGLO and SKYSONA are registered trademarks of bluebird bio, Inc. All rights reserved.

Contacts

Investors:

Courtney O’Leary, 978-621-7347
coleary@bluebirdbio.com

Media:

Jess Rowlands, 857-299-6103
jess.rowlands@bluebirdbio.com

bluebird bio, Inc.

NASDAQ:BLUE

Release Versions

Contacts

Investors:

Courtney O’Leary, 978-621-7347
coleary@bluebirdbio.com

Media:

Jess Rowlands, 857-299-6103
jess.rowlands@bluebirdbio.com

More News From bluebird bio, Inc.

Genetix Unveils Its Rapid Turnaround Into a Profitable, High-Growth Commercial Leader in Genetic Medicine for Rare Disease

SOMERVILLE, Mass.--(BUSINESS WIRE)--Genetix Biotherapeutics Inc., the commercial leader in genetic medicine for rare disease with a focus on hematology, today unveiled its rapid turnaround into a profitable commercial enterprise and announced strong 2026 commercial performance, a multibillion-dollar growth trajectory, and strategic priorities. The company shared the update in a presentation by CEO David Meek at the Jefferies Global Healthcare Conference in London, UK. Genetix has established a...

Genetix Biotherapeutics to Present at Jefferies Global Healthcare Conference

SOMERVILLE, Mass.--(BUSINESS WIRE)--Genetix Biotherapeutics Inc., the commercial leader in genetic medicine for rare disease with a focus on hematology, today announced that the Company will present at the Jefferies Global Healthcare Conference in London on Monday, November 16, at 2:30 p.m. GMT. David Meek, Chief Executive Officer of Genetix, will provide the first public update on the Company's rapid transformation into a scalable, profitable commercial enterprise, highlighting continued comme...

Genetix Biotherapeutics Appoints Meredith Manning as Chief Commercial Officer

SOMERVILLE, Mass.--(BUSINESS WIRE)--Genetix Biotherapeutics Inc., the commercial leader in genetic medicine for rare disease with a focus on hematology, today announced the appointment of Meredith Manning as Chief Commercial Officer. Ms. Manning will lead commercial strategy and execution for the company’s portfolio of FDA-approved one-time gene addition cell therapies. “Meredith is an exceptional commercial leader with a proven track record of driving growth while delivering meaningful impact...
Back to Newsroom